Toripalimab

Generic Name: Toripalimab

Brand Names: Loqtorzi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1924598-82-2

Unique Ingredient Identifier: 8JXN261VVA

Background: Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication: ⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Neoadjuvant Therapy
Immunotherapy
Non-small Cell Lung Cancer
Radiotherapy

Interventions: Drug: Toripalimab
Radiation: Conventional segmental radiotherapy
Other: opreation

First Posted Date: 2023-10-04

Last Posted Date: 2023-10-04

Lead Sponsor: Northern Jiangsu People's Hospital

Target Recruit Count: 20

Registration Number: NCT06065813

Locations: 🇨🇳
People's hospital of northern jiangsu, Yangzhou, Jiangsu, China

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Phase 2

Recruiting

Conditions: Larynx Cancer
Hypopharyngeal Cancer

Interventions: Radiation: Radiation
Procedure: Surgery
Drug: Toripalimab

First Posted Date: 2023-09-15

Last Posted Date: 2023-09-15

Lead Sponsor: Fudan University

Target Recruit Count: 82

Registration Number: NCT06039631

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: RC118
Drug: Toripalimab

First Posted Date: 2023-09-14

Last Posted Date: 2023-09-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT06038396

Locations: 🇨🇳
hongshan Hospital Affiliated to Fudan University, Shanghai, China

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6

Not Applicable

Recruiting

Conditions: Gestational Trophoblastic Neoplasia

Interventions: Drug: Toripalimab
Drug: Actinomycin-D

First Posted Date: 2023-09-08

Last Posted Date: 2023-10-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 40

Registration Number: NCT06028672

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7

Phase 2

Not yet recruiting

Conditions: Gestational Trophoblastic Neoplasia

Interventions: Drug: Toripalimab
Drug: Actinomycin-D

First Posted Date: 2023-09-01

Last Posted Date: 2023-09-05

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 17

Registration Number: NCT06020755

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer

Recruiting

Conditions: Esophageal Carcinoma

First Posted Date: 2023-08-24

Last Posted Date: 2023-08-24

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 56

Registration Number: NCT06009705

Locations: 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Phase 2

Not yet recruiting

Conditions: Neoadjuvant Therapy
Esophageal Carcinoma

Interventions: Drug: Toripalimab
Drug: Anlotinib hydrochloride
Drug: Albumin paclitaxel
Drug: Cisplatin

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-21

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 25

Registration Number: NCT05996484

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: RC48-ADC
Drug: Toripalimab
Drug: Oxaliplatin injection
Drug: Trastuzumab Injection
Drug: Capecitabine

First Posted Date: 2023-08-08

Last Posted Date: 2024-06-24

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT05980481

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation

Phase 2

Recruiting

Conditions: Muscle-Invasive Bladder Carcinoma
Programmed Cell Death Protein 1 Inhibitor
Radiotherapy

Interventions: Drug: Toripalimab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Radiation: Intensity-modulated radiation therapy

First Posted Date: 2023-08-03

Last Posted Date: 2023-12-19

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 64

Registration Number: NCT05975307

Locations: 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Adenocarcinoma of the Stomach
Adenocarcinoma of Esophagogastric Junction
Epstein-Barr Virus-Associated Gastric Carcinoma

Interventions: Drug: Toripalimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Yu jiren

Target Recruit Count: 30

Registration Number: NCT05970627

Locations: 🇨🇳
Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳
Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy